Go Pro
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel Free NVOS Stock Alerts

Novo Integrated Sciences (NVOS) Competitors

$0.0039 0.00 (0.00%)
As of 01:13 PM Eastern
Compare

NVOS vs. IMAC, BACK, AONCW, BTSGU, and LFMDP

Should you buy Novo Integrated Sciences stock or one of its competitors? Novo Integrated Sciences's main competitors and comparable companies include IMAC (IMAC), IMAC (BACK), American Oncology Network (AONCW), BrightSpring Health Services (BTSGU), and LifeMD (LFMDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Novo Integrated Sciences compare to IMAC?

Novo Integrated Sciences (NASDAQ:NVOS) and IMAC (NASDAQ:IMAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

IMAC has a net margin of -75.40% compared to Novo Integrated Sciences' net margin of -121.55%. IMAC's return on equity of -52.17% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Integrated Sciences-121.55% -93.07% -46.28%
IMAC -75.40%-52.17%-34.51%

5.7% of Novo Integrated Sciences shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Novo Integrated Sciences has a beta of 5.79, meaning that its share price is 479% more volatile than the broader market. Comparatively, IMAC has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market.

In the previous week, IMAC had 1 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 1 mentions for IMAC and 0 mentions for Novo Integrated Sciences. IMAC's average media sentiment score of 0.07 beat Novo Integrated Sciences' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
Novo Integrated Sciences Neutral
IMAC Neutral

IMAC has higher revenue and earnings than Novo Integrated Sciences. Novo Integrated Sciences is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A
IMAC$15.22M0.00-$10.54M-$0.27N/A

Summary

IMAC beats Novo Integrated Sciences on 10 of the 13 factors compared between the two stocks.

How does Novo Integrated Sciences compare to IMAC?

Novo Integrated Sciences (NASDAQ:NVOS) and IMAC (NASDAQ:BACK) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

IMAC has lower revenue, but higher earnings than Novo Integrated Sciences. Novo Integrated Sciences is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A
IMAC$72.05K0.03-$9.42M-$3.12N/A

IMAC has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. IMAC's return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Integrated Sciences-121.55% -93.07% -46.28%
IMAC N/A N/A -325.44%

5.7% of Novo Integrated Sciences shares are held by institutional investors. Comparatively, 5.8% of IMAC shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by insiders. Comparatively, 12.3% of IMAC shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Novo Integrated Sciences' average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
Novo Integrated Sciences Neutral
IMAC Neutral

Novo Integrated Sciences has a beta of 5.79, meaning that its share price is 479% more volatile than the broader market. Comparatively, IMAC has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market.

Summary

IMAC beats Novo Integrated Sciences on 7 of the 11 factors compared between the two stocks.

How does Novo Integrated Sciences compare to American Oncology Network?

American Oncology Network (NASDAQ:AONCW) and Novo Integrated Sciences (NASDAQ:NVOS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

American Oncology Network has higher revenue and earnings than Novo Integrated Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Oncology Network$1.34BN/AN/AN/AN/A
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A

American Oncology Network has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. American Oncology Network's return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
American Oncology NetworkN/A N/A N/A
Novo Integrated Sciences -121.55%-93.07%-46.28%

5.7% of Novo Integrated Sciences shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, American Oncology Network's average media sentiment score of 0.00 equaled Novo Integrated Sciences'average media sentiment score.

Company Overall Sentiment
American Oncology Network Neutral
Novo Integrated Sciences Neutral

Summary

American Oncology Network beats Novo Integrated Sciences on 4 of the 6 factors compared between the two stocks.

How does Novo Integrated Sciences compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSGU) and Novo Integrated Sciences (NASDAQ:NVOS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

BrightSpring Health Services has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. BrightSpring Health Services' return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
BrightSpring Health ServicesN/A N/A N/A
Novo Integrated Sciences -121.55%-93.07%-46.28%

In the previous week, BrightSpring Health Services had 3 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 3 mentions for BrightSpring Health Services and 0 mentions for Novo Integrated Sciences. BrightSpring Health Services' average media sentiment score of 1.61 beat Novo Integrated Sciences' score of 0.00 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company Overall Sentiment
BrightSpring Health Services Very Positive
Novo Integrated Sciences Neutral

5.7% of Novo Integrated Sciences shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BrightSpring Health Services has higher revenue and earnings than Novo Integrated Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$14.37BN/AN/AN/AN/A
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Novo Integrated Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

BrightSpring Health Services beats Novo Integrated Sciences on 7 of the 9 factors compared between the two stocks.

How does Novo Integrated Sciences compare to LifeMD?

LifeMD (NASDAQ:LFMDP) and Novo Integrated Sciences (NASDAQ:NVOS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

LifeMD has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. LifeMD's return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
LifeMDN/A N/A N/A
Novo Integrated Sciences -121.55%-93.07%-46.28%

In the previous week, LifeMD had 3 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 3 mentions for LifeMD and 0 mentions for Novo Integrated Sciences. LifeMD's average media sentiment score of 0.93 beat Novo Integrated Sciences' score of 0.00 indicating that LifeMD is being referred to more favorably in the media.

Company Overall Sentiment
LifeMD Positive
Novo Integrated Sciences Neutral

5.7% of Novo Integrated Sciences shares are owned by institutional investors. 10.4% of Novo Integrated Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LifeMD has higher revenue and earnings than Novo Integrated Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$191.59MN/AN/AN/AN/A
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A

Summary

LifeMD beats Novo Integrated Sciences on 6 of the 8 factors compared between the two stocks.

Get Novo Integrated Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVOS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVOS vs. The Competition

Export
MetricNovo Integrated SciencesHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$77K$9.76B$7.33B$13.18B
Dividend YieldN/A2.59%2.52%14.03%
P/E Ratio0.0034.78274.7625.59
Price / Sales0.015.04613.3683.42
Price / CashN/A24.1928.0235.00
Price / Book0.015.2110.536.44
Net Income-$16.17M$315.68M$3.50B$360.47M
7 Day PerformanceN/A-1.99%-1.73%-1.03%
1 Month PerformanceN/A-1.03%-3.76%-3.70%
1 Year PerformanceN/A12.92%14.48%3.62%

Novo Integrated Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVOS
Novo Integrated Sciences
N/A$0.00
flat		N/A-23.5%$77K$13.52MN/A115
IMAC
IMAC
N/A$0.00
flat		N/A-99.3%$16K$15.22MN/A106
BACK
IMAC
N/A$0.00
flat		N/A-99.3%$2K$72.05KN/A180
AONCW
American Oncology Network
N/A$0.00
flat		N/AN/A$0.00$1.34BN/A1,525
BTSGU
BrightSpring Health Services
N/A$187.22
-4.7%		N/A+99.5%$0.00$14.37BN/A35,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NVOS) was last updated on 9/28/2026 by MarketBeat.com Staff.
From Our Partners
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
This AI Stock Reminds One Analyst of Early Nvidia
Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...
Brownstone Research | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Dec 8th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel